Folgen
Peter Greasley
Peter Greasley
Early Clinical Development, AstraZeneca
Bestätigte E-Mail-Adresse bei astrazeneca.com
Titel
Zitiert von
Zitiert von
Jahr
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2
RG Pertwee, AC Howlett, ME Abood, SPH Alexander, V Di Marzo, ...
Pharmacological reviews 62 (4), 588-631, 2010
19642010
The orphan receptor GPR55 is a novel cannabinoid receptor
E Ryberg, N Larsson, S Sjögren, S Hjorth, NO Hermansson, J Leonova, ...
British journal of pharmacology 152 (7), 1092-1101, 2007
18752007
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
KM Hallow, G Helmlinger, PJ Greasley, JJV McMurray, DW Boulton
Diabetes, Obesity and Metabolism 20 (3), 479-487, 2018
4592018
Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes
MC Petrie, S Verma, KF Docherty, SE Inzucchi, I Anand, J Bělohlávek, ...
Jama 323 (14), 1353-1368, 2020
4562020
The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo
LS Whyte, E Ryberg, NA Sims, SA Ridge, K Mackie, PJ Greasley, ...
Proceedings of the national Academy of sciences 106 (38), 16511-16516, 2009
3892009
Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP‐induced receptor signaling and platelet aggregation
JJJ Van Giezen, L Nilsson, P Berntsson, BM Wissing, F Giordanetto, ...
Journal of thrombosis and haemostasis 7 (9), 1556-1565, 2009
3512009
Identification and characterisation of a novel splice variant of the human CB1 receptor
E Ryberg, HK Vu, N Larsson, T Groblewski, S Hjorth, T Elebring, ...
FEBS letters 579 (1), 259-264, 2005
2082005
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
DZI Cherney, CCJ Dekkers, SJ Barbour, D Cattran, AHA Gafor, ...
The lancet Diabetes & endocrinology 8 (7), 582-593, 2020
1922020
Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function
S Petrykiv, CD Sjöström, PJ Greasley, J Xu, F Persson, HJL Heerspink
Clinical Journal of the American Society of Nephrology 12 (5), 751-759, 2017
1642017
Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF
AM Jackson, P Dewan, IS Anand, J Bělohlávek, O Bengtsson, RA de Boer, ...
Circulation 142 (11), 1040-1054, 2020
1552020
Myc induces the nucleolin and BN51 genes: possible implications in ribosome biogenesis
PJ Greasley, C Bonnard, B Amati
Nucleic acids research 28 (2), 446-453, 2000
1492000
Mutagenesis and modelling of the α1b-adrenergic receptor highlight the role of the helix 3/helix 6 interface in receptor activation
PJ Greasley, F Fanelli, O Rossier, L Abuin, S Cotecchia
Molecular pharmacology 61 (5), 1025-1032, 2002
1402002
Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability
AJ King, M Siegel, Y He, B Nie, J Wang, S Koo-McCoy, NA Minassian, ...
Science translational medicine 10 (456), eaam6474, 2018
1102018
Mutational and Computational Analysis of the α1b-Adrenergic Receptor: INVOLVEMENT OF BASIC AND HYDROPHOBIC RESIDUES IN RECEPTOR ACTIVATION AND G PROTEIN COUPLING* 210
PJ Greasley, F Fanelli, A Scheer, L Abuin, M Nenniger-Tosato, ...
Journal of Biological Chemistry 276 (49), 46485-46494, 2001
1042001
Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the …
RA Scholtes, MHA Muskiet, MJB van Baar, AC Hesp, PJ Greasley, ...
Diabetes Care 44 (2), 440-447, 2021
922021
Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
CCJ Dekkers, CD Sjöström, PJ Greasley, V Cain, DW Boulton, ...
Diabetes, Obesity and Metabolism 21 (12), 2667-2673, 2019
912019
Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus
AS Go, J Yang, TC Tan, CS Cabrera, BV Stefansson, PJ Greasley, ...
BMC nephrology 19, 1-13, 2018
872018
Big pharma screening collections: more of the same or unique libraries? The AstraZeneca–Bayer Pharma AG case
T Kogej, N Blomberg, PJ Greasley, S Mundt, MJ Vainio, J Schamberger, ...
Drug discovery today 18 (19-20), 1014-1024, 2013
802013
Scaffold hopping, synthesis and structure–activity relationships of 5, 6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists
J Boström, K Berggren, T Elebring, PJ Greasley, M Wilstermann
Bioorganic & medicinal chemistry 15 (12), 4077-4084, 2007
752007
N-Arachidonoyl-l-Serine is Neuroprotective after Traumatic Brain Injury by Reducing Apoptosis
A Cohen-Yeshurun, V Trembovler, A Alexandrovich, E Ryberg, ...
Journal of Cerebral Blood Flow & Metabolism 31 (8), 1768-1777, 2011
642011
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20